Anatara reports statistically significant animal studies and completes successful GaRP preclinical testing
BRISBANE & MELBOURNE, October 14, 2019
Anatara Lifesciences Ltd is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product. GaRP is a proprietary dietary supplement designed to restore and maintain a healthy human gut and microbiome.
Highlights
- Successful completion of the preclinical program has provided strong scientific proof that the GaRP dietary supplement has the potential to be game changing
- When compared to a placebo control, GaRP reduced the combined disease characteristics of colon inflammation and disrupted bowel habits by 2.5-fold (p=0.012)
- Promoted mucosal healing by increasing mucin genes by a factor of 5 to 7-fold (MUC2 and MUC6, p<0.001)
At the completion of the preclinical development, GaRP's proprietary formulation has provided strong scientific evidence that it can combat the three underlying causes of chronic gastrointestinal conditions. In summary, GaRP:
- Addressed the dysbiosis of the microbiome
- Reduced gut inflammation
- Promoted mucosal healing
Please click here to view the ASX announcement.
|
